Clinical Trials Update: Medical Management of Advanced Breast Cancer

Cancer Nursing

Volumn 26, Issue 6 SUPPL., 2003, Pages

  Major, Maureen A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Aromatase inhibitors; Bisphosphanates; HER2; Hormonal therapy; Metastatic breast cancer; Monoclonal antibodies

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; LETROZOLE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PAMIDRONIC ACID; PLATINUM; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ADVANCED CANCER; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HORMONE SENSITIVITY; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0347381143     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. McEvilly JM, Dow KH. Treating metastatic breast cancer: principles and current practice. Am J Nurs. 1998;(suppl):26-29.
2. National Comprehensive Cancer Network (NCCN). Practice guidelines-breast cancer. Version 2.2002. Available at: http://www.nccn.org. Accessed April 3, 2003.
3. Lippman ME. Endocrine-responsive cancer. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders Co; 1998:1675-1692.
4. Terakawa N. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview. Oncology. 2000;59(suppl 1):3-4.
5. Dees EC, Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol. 2001;28:322-331.
6. Powles TJ. Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol. 1997;24(suppl 1):S1-S54.
7. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol. 1997;24(suppl 1):S1-S19.
8. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386-3395.
9. Howell A, Robertson JFR, Albano JQ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396-3403.
10. Buzdar AU, Jonat W, Howell A, et al, for the Arimidix Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer. 1998;83:1142-152.
11. Dombernowsky P, Smith G, Falkson R, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453-461.
12. Rose C, Vtoraya O, Pluzanska A, et al. Lerrozole (Femara) vs anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002. Abstract 131.
13. Bonneterre J, Thürlimann B, Robertson JFR, et al, for the Arimidex Study Group. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 2000;18:3748-3757.
14. Nabholtz JM, Buzdar A, Pollak M, et al, for the Arimidix Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000;18:3758-3767.
15. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596-2606.
16. Dirix L, Piccart MJ, Lohrisch C, et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormonal therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Cancer Group) Phase II trial with Pharmacia and Upjohn [abstract]. Proc Am Soc Clin Oncol. 2001. Abstract 114.
17. Jones S, Vogel C, Arkhipov A, et al, for the Aromasin Study Group. Multicenter phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol. 1999;17:3418-3425.
18. Lönning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase III trial. J Clin Oncol. 2000;18:2234-2244.
19. Kaufman M, Bajetta E, Dirix LY, et al, for the Exemestane Study Group. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000;18:1399-1411.
20. Lohrisch C, Paridaens R, Dirix LY, et al. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (exemestane [E]) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organization for Research and Treatment of Cancer (Breast Group) trial with Pharmacias' Upjohn [abstract]. Proc Am Soc Clin Oncol. 2001. Abstract 167.
21. Crown J, Dieras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer: report of a European expert panel. Lancet Oncol. 2002;3:719-727.
22. Burstein HJ, Bunnell CA, Winer EP, New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001;28:344-358.
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
24. Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic factors. J Clin Oncol. 1998;16:462-469.
25. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001;28(suppl 18):43-47.
26. Bast RC Jr, Ravdin P, Hayes DF, et al, for the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
27. Perez EA. Metastatic bone disease in breast cancer: the patient's perspective. Semin Oncol. 2001;28(suppl 11):60-63.